Mount Sinai Health System and Memorial Sloan Kettering Cancer Center researchers have developed a new drug delivery approach that uses nanoparticles to enable more effective and targeted delivery of anti-cancer drugs to treat brain tumors in children.
Tag: Medulloblastoma
McMaster University researchers pinpoint potential treatment for lethal childhood cancer
Researchers discovered that by blocking the production of an enzyme called DHODH, they were able to halt the growth of MYC gene-amplified medulloblastoma in mouse models, the most aggressive subtype of this cancer.
Rhombic lip implicated in origins of high-risk medulloblastoma
Scientists from St. Jude Children’s Research Hospital found that group 3 and 4 medulloblastoma arise from the rhombic lip, knowledge that may help improve research models and therapeutic development.
Combining Two ‘Old Therapies’ Packs a Powerful Punch Against Pediatric Brain Tumors
Researchers at Johns Hopkins Medicine and Italy’s Catholic University of the Sacred Heart medical school have provided solid evidence that copper, the first metal used medicinally, may now have a new role — helping save children from a devastating central nervous system cancer known as medulloblastoma.
Cell-free DNA identifies early signs of relapse in pediatric medulloblastoma
Findings from St. Jude Children’s Research Hospital show that cell-free DNA in cerebrospinal fluid can be used to detect measurable residual disease and identify patients at risk of relapse.
Study sheds light on treatment options for devastating childhood brain cancer
A new study led by Washington University School of Medicine in St. Louis provides new guidance on the treatment of medulloblastoma, a pediatric brain cancer. Some aspects of radiation therapy may be reduced while still providing effective treatment.
Targeting Abnormal Cell Metabolism Shows Promise for Treating Aggressive Pediatric Brain Tumors
Two experimental drug approaches that target vulnerabilities in cancer cell metabolism may extend survival and enhance the effectiveness of standard chemotherapies for a highly aggressive type of pediatric brain cancer.
From the clinic to the lab, understanding medulloblastoma relies on molecular profiling
A pair of research papers from St. Jude Children’s Research Hospital report on a medulloblastoma clinical trial that provides insights to guide treatment and shed light on relapsed disease.
Personalized drug screens could guide treatment for children with brain cancer
Scientists at Sanford Burnham Prebys Medical Discovery Institute, University of California San Diego School of Medicine and Hopp Children’s Cancer Center Heidelberg (KiTZ) have demonstrated that personalized drug screens can be used to identify new therapeutic candidates for medulloblastoma. The approach measures the effectiveness of therapeutics using tumor cells obtained from a biopsy and can be performed in a few days—making it one of the quickest sources of information used in clinical decision-making.
New chemotherapy drug studied for malignant brain tumor in children
MTX110 is a new formulation of panobinostat, a chemotherapy drug that has shown promise in laboratory models of medulloblastoma, the most common malignant brain tumor in children. Now, MTX110 is the focus of a novel trial that places the therapy directly into the fourth ventricle of the brain to treat patients with recurrent medulloblastoma.
Scientists identify promising immunotherapy combination for pediatric brain cancer
Scientists at Sanford Burnham Prebys have discovered that combining immunotherapy with a drug called tumor necrosis factor (TNF) eradicated a deadly type of pediatric brain tumor in mice. The discovery, published in Nature Neuroscience, is expected to lead to a clinical trial to test the benefits of the treatment in patients. The findings also hold implications for other cancers that do not respond to immunotherapy.
Inherited mutation can predispose children to a type of brain tumor
Collaboration co-led by researchers at St. Jude Children’s Research Hospital discovers a novel predisposition gene in pediatric medulloblastoma.
Targeting a transporter to treat SHH medulloblastoma
Scientists at St. Jude Children’s Research Hospital have identified a novel target for a type of pediatric brain tumor.
Researchers identify possible approach to block medulloblastoma growth
University of North Carolina Lineberger Comprehensive Cancer Center researchers have identified a potential approach to stop the growth of the most common type of brain tumor in children.
Leukemia Drug Shows Promise for Treating a Childhood Brain Cancer
Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego researchers describe new use of leukemia drug, nilotinib, to treat subtype of medulloblastoma, a deadly pediatric brain cancer.